Proceedings of the International Symposium on Tuberculosis Vaccine Development and EvaluationClinical infectious diseases. 2000, Vol 30, issn 1058-4838, 127 p., SUP3Conference Proceedings

Evaluation of vaccines to prevent childhood pneumonia : Lessons relevant to planning tuberculosis vaccine trialsMULHOLLAND, K.Clinical infectious diseases. 2000, Vol 30, pp 206-209, issn 1058-4838, SUP3Conference Paper

Immunologic diagnosis of tuberculosisGENNARO, M. L.Clinical infectious diseases. 2000, Vol 30, pp 243-246, issn 1058-4838, SUP3Conference Paper

A large, simple trial of a tuberculosis vaccineHORSBURGH, C. R.Clinical infectious diseases. 2000, Vol 30, pp 213-216, issn 1058-4838, SUP3Conference Paper

Current tuberculosis vaccine developmentYOUNG, D. B.Clinical infectious diseases. 2000, Vol 30, pp 254-256, issn 1058-4838, SUP3Conference Paper

Simple, practical ways to assess the protective efficacy of a new tuberculosis vaccineCOMSTOCK, G. W.Clinical infectious diseases. 2000, Vol 30, pp 250-253, issn 1058-4838, SUP3Conference Paper

Ethical issues in tuberculosis vaccine trialsSNIDER, D. E.Clinical infectious diseases. 2000, Vol 30, pp 271-275, issn 1058-4838, SUP3Conference Paper

Moving new vaccines for tuberculosis through the regulatory processBRENNAN, M. J.Clinical infectious diseases. 2000, Vol 30, pp 247-249, issn 1058-4838, SUP3Conference Paper

Aluminium adjuvants in vaccines: workshop summary, San Juan, Puerto Rico, 11-12 May 2000POLAND, G. A.Vaccine. Supplement. 2002, Vol 20, issn 1359-5938, 66 p., 3Conference Proceedings

Diagnostic test needs for evaluating antituberculosis vaccinesSHINNICK, T. M.Clinical infectious diseases. 2000, Vol 30, pp 276-278, issn 1058-4838, SUP3Conference Paper

From pertussis to tuberculosis : What can be learned?KLEIN, D. L.Clinical infectious diseases. 2000, Vol 30, pp 302-308, issn 1058-4838, SUP3Conference Paper

Improving vaccine performance with adjuvantsVOGEL, F. R.Clinical infectious diseases. 2000, Vol 30, pp 266-270, issn 1058-4838, SUP3Conference Paper

Clinical considerations in designing trials of vaccines for tuberculosisGLASSROTH, J.Clinical infectious diseases. 2000, Vol 30, pp 229-232, issn 1058-4838, SUP3Conference Paper

An overview of the proceedings of the international symposium on tuberculosis vaccine development and evaluation : Recognizing and addressing the barriersBREIMAN, R. F; GINSBERG, A. M.Clinical infectious diseases. 2000, Vol 30, pp 199-200, issn 1058-4838, SUP3Conference Paper

Potential impact of tuberculosis vaccines as epidemic control agentsLIETMAN, T; BLOWER, S. M.Clinical infectious diseases. 2000, Vol 30, pp 316-322, issn 1058-4838, SUP3Conference Paper

Correlates of protective immunity to Mycobacterium tuberculosis in humansELLNER, J. J; HIRSCH, C. S; WHALEN, C. C et al.Clinical infectious diseases. 2000, Vol 30, pp 279-282, issn 1058-4838, SUP3Conference Paper

Desirable immunologic characteristics for the development of an ideal vaccineADA, G.International journal of technology assessment in health care. 1994, Vol 10, Num 1, pp 71-80, issn 0266-4623Conference Paper

Absence of viral sequences in the who-vero cell bank a collaborative studyHORAUD, F.Developments in biological standardization. 1992, Num 76, pp 43-46, issn 0301-5149Conference Paper

Durable cure for tuberculosis : Rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infectionSHOEN, C. M; DESTEFANO, M. S; CYNAMON, M. H et al.Clinical infectious diseases. 2000, Vol 30, pp 288-290, issn 1058-4838, SUP3Conference Paper

Conference on vaccines and public healthFREEMAN, Phyllis; RABINOVICH, Regina; ROBBINS, Anthony et al.International journal of technology assessment in health care. 1994, Vol 10, Num 1, issn 0266-4623, 198 p.Conference Proceedings

Synthetic peptides and purified antigens as vaccinesBROWN, F.International journal of technology assessment in health care. 1994, Vol 10, Num 1, pp 161-166, issn 0266-4623Conference Paper

Mucosal bacille Calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-γ responsesHOFT, D. F; BROWN, R. M; BELSHE, R. B et al.Clinical infectious diseases. 2000, Vol 30, pp 217-222, issn 1058-4838, SUP3Conference Paper

Continuous cell lines : an international workshop on current issuesDevelopments in biological standardization. 1992, Num 76, issn 0301-5149Conference Proceedings

Validation of virus removal in large scale purification processesFRITSCH, E.Developments in biological standardization. 1992, Num 76, pp 239-248, issn 0301-5149Conference Paper

Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE)ROHWER, R. G.Developments in biological standardization. 1996, Num 88, pp 247-256, issn 0301-5149Conference Paper